C4d Antibody |
|||
DF13993 | Affbiotech | 100ul | EUR 420 |
C4d Antibody |
|||
DF13993-100ul | Affinity Biosciences | 100ul | EUR 280 |
C4d Antibody |
|||
DF13993-200ul | Affinity Biosciences | 200ul | EUR 350 |
C4d, Antibody |
|||
GWB-642521 | GenWay Biotech | 1 ml | Ask for price |
C4d, Antibody |
|||
GWB-E746F7 | GenWay Biotech | 7 ml | Ask for price |
C4d Antibody |
|||
GWB-822CB1 | GenWay Biotech | 0.1 mg | Ask for price |
C4d Antibody (Neoantigen) |
|||
GWB-38EC16 | GenWay Biotech | 0.1 mg | Ask for price |
Anti-Human C4d antibody |
|||
STJ16101318 | St John's Laboratory | 1 mL | EUR 1138.8 |
Anti-Human C4d antibody |
|||
STJ16101454 | St John's Laboratory | 1 mL | EUR 1138.8 |
Complement C4d(C4D204) Antibody |
|||
BNCH0204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNCH0204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNCH0205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNCH0205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC700204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), CF770 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC700204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), CF770 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC700205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), CF770 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC700205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), CF770 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC800204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), CF680 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC800204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), CF680 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC800205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), CF680 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC800205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), CF680 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC810204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), CF680R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC810204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), CF680R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC810205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), CF680R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC810205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), CF680R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC550204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), CF555 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC550204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), CF555 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC550205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), CF555 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC550205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), CF555 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC430204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), CF543 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC430204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), CF543 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC430205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), CF543 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC430205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), CF543 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC610204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), CF660R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC610204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), CF660R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC610205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), CF660R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC610205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), CF660R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC050204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), CF405M conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNC050204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), CF405M conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC050205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), CF405M conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNC050205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), CF405M conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNCA0204-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against Complement C4d(C4D204), APC conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNCA0205-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against Complement C4d(C4D205), APC conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNCAP0204-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D204), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNCAP0204-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D204), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNCAP0205-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4D205), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNCAP0205-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4D205), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNCP0204-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against Complement C4d(C4D204), PerCP conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNCP0205-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against Complement C4d(C4D205), PerCP conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D204) Antibody |
|||
BNCR0204-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against Complement C4d(C4D204), RPE conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4D205) Antibody |
|||
BNCR0205-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against Complement C4d(C4D205), RPE conjugate, Concentration: 0.1mg/mL |
OASA11515-100UG - C4d Antibody |
|||
OASA11515-100UG | Aviva Systems Biology | 0.1mg | EUR 309 |
C4d / Complement 4d Antibody |
|||
V9091-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
Description: This mAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V9091-20UG | NSJ Bioreagents | 20 ug | EUR 186.15 |
Description: This mAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V9091IHC-7ML | NSJ Bioreagents | 7 ml | EUR 424.15 |
Description: This mAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V9091SAF-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
Description: This mAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V7025-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
Description: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V7025-20UG | NSJ Bioreagents | 20 ug | EUR 186.15 |
Description: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V7025SAF-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
Description: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V2021-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
Description: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V2021-20UG | NSJ Bioreagents | 20 ug | EUR 186.15 |
Description: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V2021CF488-100T | NSJ Bioreagents | 100 Tests | EUR 424.15 |
Description: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V2021IHC-7ML | NSJ Bioreagents | 7 ml | EUR 424.15 |
Description: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
C4d / Complement 4d Antibody |
|||
V2021SAF-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
Description: This antibody is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound protein. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of antibodies to specific target molecules. Following activation and degradation of the C4 molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product C4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. C4d has been shown to be a significant predictor of transplant kidney graft survival. C4d antibody, combined with antibody to C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment. |
Complement C4d(C4203) Antibody |
|||
BNCH0203-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4203), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNCH0203-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4203), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNCAP1232-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(TDM16), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNCAP1232-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(TDM16), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNCH1232-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(TDM16), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNCH1232-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(TDM16), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC700203-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4203), CF770 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC700203-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4203), CF770 conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC701232-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(TDM16), CF770 conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC701232-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(TDM16), CF770 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC800203-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4203), CF680 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC800203-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4203), CF680 conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC801232-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(TDM16), CF680 conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC801232-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(TDM16), CF680 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC810203-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4203), CF680R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC810203-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4203), CF680R conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC811232-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(TDM16), CF680R conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC811232-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(TDM16), CF680R conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC550203-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4203), CF555 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC550203-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4203), CF555 conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC551232-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(TDM16), CF555 conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC551232-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(TDM16), CF555 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC430203-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(C4203), CF543 conjugate, Concentration: 0.1mg/mL |
Complement C4d(C4203) Antibody |
|||
BNC430203-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(C4203), CF543 conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC431232-100 | Biotium | 100uL | EUR 238.8 |
Description: Primary antibody against Complement C4d(TDM16), CF543 conjugate, Concentration: 0.1mg/mL |
Complement C4d(TDM16) Antibody |
|||
BNC431232-500 | Biotium | 500uL | EUR 652.8 |
Description: Primary antibody against Complement C4d(TDM16), CF543 conjugate, Concentration: 0.1mg/mL |